Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

DECEMBER 23, 2016
Jeffrey Jones, MD,
In this interview during the 58th Annual ASH Meeting & Exposition, Jeffrey Jones, MD, MPH, of the division of Hematology at Ohio State University talks about a recent phase 1b study involving the use of obinutuzmab, ibritinib, and venetoclax to treat relapsed/refractory chronic lymphocytic leukemia (CLL).
 

Reference

Jones JA, Woyach J, Awan FT, et al. 639 Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016. Abstract 639.


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.